Substrate
finance

Arms Sale to Taiwan Remains Under Review

The proposed $14 billion arms sale to Taiwan is still being evaluated. Officials have not announced a final decision on the package.

FI
middleeasteye.net
2 sources·Jun 2, 11:14 AM·1m read
Arms Sale to Taiwan Remains Under Reviewmiddleeasteye.net
Audio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.

A proposed $14 billion arms sale to Taiwan remains under review, U.S. Secretary of State Rubio stated. The review covers weapons systems and related equipment intended for Taiwan's defense forces.

No timeline for completion of the review was provided.

Officials said the process continues without a set deadline. The sale would require formal notification to Congress if approved.

Transparency

Confidence75%

2 independent outlets report the same core facts. This score blends how many outlets corroborate, their editorial tier, and how closely their facts agree — it measures corroboration, not proof.

Story details

Related Stories

U.S. Strikes Botswana-Flagged Tanker in International Waters; Iran Blockade in Effectthehindu.com
finance45 min ago

U.S. Strikes Botswana-Flagged Tanker in International Waters; Iran Blockade in Effect

A U.S. aircraft fired an AGM-114 Hellfire missile into the engine room of the M/T Lexie on Tuesday, disabling the unladen vessel as it headed toward Kharg Island. The strike followed repeated ignored warnings over 24 hours.

FI
FI
OS
BBC News
4 sources
Fed Chairman Names Two Outside Advisers During Transitionprnewswire.com
finance45 min ago

Fed Chairman Names Two Outside Advisers During Transition

Federal Reserve Chairman Kevin Warsh appointed two interim advisers shortly after taking the post. One previously contributed to a conservative plan calling for major changes at the central bank.

FI
Wall Street Journal
2 sources
Forte Biosciences Accepts Resignation of Director David Veitchinsidermonkey.com
finance2 hrs agoSourced

Forte Biosciences Accepts Resignation of Director David Veitch

Forte Biosciences disclosed the resignation of independent director David Veitch from its board effective June 1 2026. The departure reduces the company's board size and triggers standard SEC and Nasdaq disclosure obligations for director changes at the clinical-stage biopharmace…

SEC EDGAR — Forte Biosciences, Inc. (FBRX)
1 source